Indeed, beyond its effects on LDL metabolism, several studies have demonstrated the existence of additional roles of PCSK9 in different stages of atherosclerosis through its interaction with other receptors, such as LRP1, ApoER2, and CD36. The gene discussed is CD36; the disease is atherosclerosis.